Mirae Asset Global Investments Co., Ltd. - SAREPTA THERAPEUTICS INC ownership

SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 455 filers reported holding SAREPTA THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.01 and the average weighting 0.2%.

Quarter-by-quarter ownership
Mirae Asset Global Investments Co., Ltd. ownership history of SAREPTA THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$11,620,755
+11.4%
95,865
+5.2%
0.03%
+18.2%
Q2 2023$10,427,927
-18.2%
91,102
-1.5%
0.02%
-26.7%
Q1 2023$12,744,175
+11.3%
92,463
+4.6%
0.03%0.0%
Q4 2022$11,452,669
-17.5%
88,383
-29.6%
0.03%
-18.9%
Q3 2022$13,876,000
+62.9%
125,530
+10.5%
0.04%
+68.2%
Q2 2022$8,517,000
-59.1%
113,622
-57.4%
0.02%0.0%
Q1 2022$20,842,000
+49.2%
266,806
+71.9%
0.02%
-26.7%
Q4 2021$13,973,000
-13.9%
155,171
-11.5%
0.03%
-26.8%
Q3 2021$16,221,000
+47.0%
175,397
+23.5%
0.04%
+32.3%
Q2 2021$11,037,000
+163.0%
141,973
+152.2%
0.03%
+106.7%
Q1 2021$4,197,000
-23.5%
56,303
+75.1%
0.02%
-25.0%
Q4 2020$5,483,000
+66.6%
32,160
+37.2%
0.02%
+25.0%
Q3 2020$3,291,000
+18.3%
23,436
+35.1%
0.02%
-5.9%
Q2 2020$2,781,000
+85.8%
17,344
+13.4%
0.02%
+41.7%
Q1 2020$1,497,000
-10.0%
15,298
+18.6%
0.01%
+20.0%
Q4 2019$1,664,000
+144.0%
12,898
+42.4%
0.01%
+100.0%
Q3 2019$682,000
-22.2%
9,060
+56.9%
0.01%
-16.7%
Q2 2019$877,000
+75.4%
5,774
+37.6%
0.01%
+50.0%
Q1 2019$500,0004,1950.00%
Other shareholders
SAREPTA THERAPEUTICS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Casdin Capital, LLC 1,315,000$170,397,70013.20%
EcoR1 Capital, LLC 2,999,453$388,669,12011.83%
Evolutionary Tree Capital Management, LLC 63,756$8,261,5027.93%
Tri Locum Partners LP 119,695$15,510,0006.27%
Avoro Capital Advisors LLC 3,175,000$411,416,5006.15%
Camber Capital Management LP 1,250,000$161,9755.56%
Finepoint Capital LP 131,457$17,0345.51%
ACUTA CAPITAL PARTNERS, LLC 67,500$8,746,6505.38%
Logos Global Management LP 220,000$28,507,6003.34%
AFG FIDUCIARY SERVICES LIMITED PARTNERSHIP 33,454$3,401,6573.20%
View complete list of SAREPTA THERAPEUTICS INC shareholders